Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity

NCT02496611 on ClinicalTrials.gov · last registry update 2022-01-03

Finished 14 August 2020, after enrolling 100 people. Primary outcome, as filed: Body Mass Index. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: University of Minnesota
Sponsor type: Other
Enrollment: 100
Started: 2015-12
Primary completion: 2020-08-14 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Body Mass Index

Conditions studied

Severe Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.